Compare Illumina, Inc. (ILMN) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Tesla, Inc. — how do they compare? Illumina, Inc. trades at $268.39 (market cap $39.95B), while Tesla, Inc. trades at $385.8 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 37× Illumina, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Tesla, Inc. for 88 Days on average.
| ILMN | TSLA | |
|---|---|---|
Market Cap | $39.95B | $1.48T |
Volume | 3,169,503 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $489.88 |
52-Week Low | $91.00 | $298.16 |
Typical Hold Time | 83 Days | 88 Days |
Enterprise Value | $41.31B | $1.45T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Tesla (TSLA) trades at $377.61, down 0.81% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, missing EPS estimates, while revenue has softened slightly in 2025. Analyst consensus remains positive with a $441.36 price target, and recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.
Tesla's outlook balances innovation in autonomy and energy against near-term earnings pressure and high valuations. Investment opportunities lie in AI and robotaxi growth, but risks include intense EV competition, execution on new technologies, and profitability concerns given a P/E of 347.22. The stock's performance hinges on delivering future growth to justify its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
